NomosLogic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100,000 American Lives Each Year

SALT LAKE CITY--(BUSINESS WIRE)-- #ADRPrevention--NomosLogic, Inc., a deterministic molecular medicine infrastructure company headquartered in Salt Lake City, announced today that the company will be present at the 2026 BIO International Convention from June 22 to 25 at the San Diego Convention Center. Founder and CEO Matthew Hardy and SVP of Business Development Jai DeJong will be available for one-to-one meetings through BIO Partnering and open conversations with payer organizations, biopharmaceutical partner